News stories about Idera Pharmaceuticals (NASDAQ:IDRA) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.0269048298383 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several equities analysts have recently weighed in on the company. Piper Jaffray Companies restated a “buy” rating and issued a $4.00 price objective on shares of Idera Pharmaceuticals in a report on Tuesday, September 12th. ValuEngine upgraded Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. BidaskClub cut Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Finally, Zacks Investment Research upgraded Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. Three analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Idera Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $4.48.

Idera Pharmaceuticals (NASDAQ:IDRA) traded down 1.33% during trading on Friday, reaching $2.23. The company had a trading volume of 566,680 shares. The company’s market capitalization is $333.68 million. Idera Pharmaceuticals has a one year low of $1.30 and a one year high of $3.33. The company has a 50-day moving average price of $1.89 and a 200 day moving average price of $1.94.

Idera Pharmaceuticals (NASDAQ:IDRA) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.03). Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Analysts expect that Idera Pharmaceuticals will post ($0.49) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Idera Pharmaceuticals (IDRA) Receives Media Impact Rating of 0.11” was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.

Insider Buying and Selling by Quarter for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.